Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
ABRA Trial PMID 39615502
Related Questions
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Have you observed adverse mental health side effects in patients who start montelukast?
How do you choose roflumilast vs ensifentrine in COPD patients with dyspnea despite adequate LABA + LAMA (+ ICS therapy where indicated)?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you prescribe lower dose ICS for asthma to mitigate the risk of pneumonia in patients with a history of respiratory infections or compromised immune systems?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
What is your preferred rescue inhaler for patients with asthma?